Breast Cancer: Novel Insights into Hormone Therapy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".
Deadline for manuscript submissions: closed (20 April 2024) | Viewed by 1647
Special Issue Editor
Special Issue Information
Dear Colleagues,
Endocrine therapy is the standard of care in hormone-receptor-positive breast cancer (HR+ BC).
Understanding the mechanisms of intrinsic resistance in addition to the molecular pathways activated by cancer cells after exposure to endocrine therapy has led to the development of highly active treatments, some of which have resulted in significantly improved survival.
CDK4/6 inhibitors are now part of clinical practice in adjuvant and metastatic settings; many clinical trials are exploring the role of new targeted agents in adjuvant and neoadjuvant settings of the disease.
Other new drugs (SERDs, CDK7 inhibitors, and PI3K/akt/mTor inhibitors) are increasingly appearing in metastatic settings. Moreover, antibody-drug conjugates (ADCs) have recently demonstrated their clinical efficacy regardless of the expression of hormone receptors, as have PROTACTs (PROteolysis Targeting Chimeras), new small molecules designed to escape endocrine resistance mechanisms.
The aim of this Special Issue is to report the state of the art in the treatment of HR+ BC and analyze the new challenges to be addressed: redefining escalation and de-escalation strategies based on the risk of disease recurrence in an adjuvant setting and on the disease burden in a metastatic setting; identifying the optimal treatment sequence; understanding the role of ADCs in HR+ BC and the role of predictive biomarkers of responses that have been identified so far (PI3K, BRCA, and ESR1 mutations, as well as, more recently, the low expression of HER2).
Dr. Palma Fedele
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormone-positive breast cancer
- targeted therapy
- endocrine therapy
- CDK 4/6 inhibitors
- PI3K inhibitors
- ADCs
